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Abstract
Background: Recent genome-wide association studies (GWAS) have identified novel loci associated with sudden cardiac
death (SCD). Despite this progress, identified DNA variants account for a relatively small portion of overall SCD risk,
suggesting that additional loci contributing to SCD susceptibility await discovery. The objective of this study was to identify
novel DNA variation associated with SCD in the context of coronary artery disease (CAD).
Methods and Findings: Using the MetaboChip custom array we conducted a case-control association analysis of
119,117 SNPs in 948 SCD cases (with underlying CAD) from the Oregon Sudden Unexpected Death Study (Oregon-SUDS)
and 3,050 controls with CAD from the Wellcome Trust Case-Control Consortium (WTCCC). Two newly identified loci were
significantly associated with increased risk of SCD after correction for multiple comparisons at: rs6730157 in the RAB3GAP1
gene on chromosome 2 (P= 4.93610212, OR = 1.60) and rs2077316 in the ZNF365 gene on chromosome 10 (P = 3.6461028,
OR = 2.41).
Conclusions: Our findings suggest that RAB3GAP1 and ZNF365 are relevant candidate genes for SCD and will contribute to
the mechanistic understanding of SCD susceptibility.
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Introduction
Sudden cardiac death (SCD) remains a significant public health
problem with an estimated annual incidence of 250,000–300,000
in the US and 4–5 million around the globe [1–3]. Although
coronary artery disease (CAD) underlies the majority of SCD [4],
there is a significant familial component to SCD risk which
appears to be distinct from that associated with other manifesta-
tions of atherosclerosis in population-based studies [5–7]. Recent
collaborative genome-wide association (GWA) efforts have iden-
tified susceptibility loci associated with SCD [8–10] but only two
DNA variants on chromosomes 2q24 (BAZ2B) [10] and 21q21
(near CXADR) [9] have crossed the stringent threshold of genome-
wide statistical significance. While candidate-gene based studies
have also yielded DNA variants associated with SCD these may
not constitute an unbiased approach [11–13]. We hypothesized
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that the distinct configuration of the MetaboChip custom array
which contains variants nominally associated (P,0.01) with CAD,
QT interval, systolic and diastolic blood pressure, diabetes,
glycemic traits, lipids, height and weight in large-scale meta-
analyses of GWA studies [14] would enable the identification of
additional novel genetic variation associated with SCD in the
context of CAD. Accordingly, we conducted a case-control
association study using SCD cases from the Oregon Sudden
Unexpected Death Study (Oregon-SUDS) and controls with CAD
from the Wellcome Trust Case-Control Consortium (WTCCC+).
Methods
Study Subjects
Ethics statement. All samples have been established in
accordance with the principles expressed in the Declaration of
Helsinki. The study was approved by the Institutional Review
Boards of Oregon Health and Science University, Legacy Health
Systems, VA Medical Center, Portland OR and the WTCCC
Data Access Committee. Written informed consent was obtained
from all enrolled subjects. If subjects were deceased at the time of
ascertainment (i.e. following a sudden cardiac death) consent was
waived by the respective Institutional Review Boards on grounds
of scientific feasibility. These latter subjects were de-identified for
the purpose of analysis, in conformation with procedures approved
by the respective Institutional Review Boards.
Oregon-SUDS. A total of 979 SCD cases of European
descent were ascertained from the Oregon-SUDS, an ongoing
community-based study among residents of the Portland, Oregon
metropolitan area. Detailed methodology has been reported
previously [15–18]. Briefly, SCD cases are identified from the
emergency medical response system, the medical examiner
network and 16 local hospitals. All available medical records are
obtained for each subject. SCD was defined as an unexpected
pulseless condition likely of cardiac origin. If unwitnessed, SCD
was defined as unexpected death within 24 hours of having last
been seen alive and in normal state of health [19]. All SCD cases
included in this study were required to have documented coronary
artery disease (CAD). CAD was defined as 50% stenosis of a major
coronary artery, physician report of past myocardial infarction
(MI), history of percutaneous coronary intervention (PCI) or
coronary artery bypass grafting (CABG); or autopsy-identified
CAD; or MI by clinical data with any two of the following three:
ischemic symptoms, positive troponins or CKMB; or pathologic Q
waves on ECG. SCD cases with chronic terminal illnesses, known
non-cardiac causes of SCD, traumatic deaths and drug overdose
were excluded from the analysis.
WTCCC+ controls. The control samples for this study
comprised 3,219 pooled subjects from 4 UK studies: (i) CAD
cases recruited into the British Heart Foundation Family Heart
Study [20] (n = 2169, 78.6% males, 70.8% MI, 68.6% CABG/
PCI, mean age at diagnosis 49.967.7 years), including the 1,926
subjects analyzed in the original WTCCC Study [21]; (ii) Young
MI cases with an event below the age of 50 years recruited into the
Premature Acute Myocardial Infarction Study (PRAMIS) [22]
(n = 214, 85.5% males, mean age at event 42.465.8 years); (iii) MI
cases recruited into the Secondary Prevention of Acute Coronary
Events - Reduction of Cholesterol to Key European Targets
(SPACE ROCKET) Trial [23] (n = 499, 84.0% males, mean age
at event 57.768.4 years); (iv) MI cases recruited in the Outcomes
from Percutaneous coronary intervention by Evaluation of Risk
Attributes (OPERA) Trial [24] (n = 337, 75.5% males, mean age
at event 55.868.4 years). CAD status and diagnosis was validated
in all studies by direct review of clinical notes. All subjects were of
White European origin. The choice of CAD controls (as opposed
to population-based controls) was based on the recognition that
over 80% of SCDs occur in the setting of CAD. Accordingly, CAD
controls would enable the discovery of genetic associations
exclusively related to SCD and independent of CAD [25].
MetaboChip Array
The MetaboChip array (Illumina, San Diego, CA) is a custom
Illumina iSelect genotyping array comprised of approximately
200,000 SNPs selected from previous GWAS meta-analyses
findings from the CARDIoGRAM (coronary artery disease),
DIAGRAM (type 2 diabetes), GIANT (height and weight),
MAGIC (glycemic traits), Lipids (lipids), ICBP-GWAS (blood
pressure), and QT-IGC (QT interval) consortia [14]. The array
comprises a linkage-disequilibrium pruned set of SNPs that
reached a nominal level (P,0.01) of association with each of
these diseases/phenotypes as well as SNP sets for fine-mapping of
loci identified for these disease/traits at the time of design of the
array. Additional details of the MetaboChip design can be found
at: www.sph.umich.edu/csg/kang/MetaboChip/.
MetaboChip Genotyping and Statistical Analysis
Genotyping of SCD cases was performed at the Medical
Genetics Institute at Cedars-Sinai Medical Center, Los Angeles,
U.S. and controls were genotyped at the Wellcome Trust Sanger
Centre, Hinxton, UK using the same array. After exclusion of
array failures, poor quality genotypes and duplicates, 948 SCD
cases and 3,050 CAD controls were used in the current analyses.
Genotypes in both studies were called using the GenCall
algorithm [26,27]. Individual SNPs were excluded from analysis
using standard quality control criteria based on sample call rates
less than 90%, Hardy-Weinberg Equilibrium (HWE) P,161024,
monomorphic and SNPs with minor allele frequencies (MAF) less
than 1%. This left 119,117 post-QC SNPs for analysis. Association
analyses were performed using logistic regression assuming an
additive model adjusting for age, sex and the first 3 dimensions
from multi-dimensional scaling (PLINK software) [28]. Results
were further corrected for the genomic control factor (l), which
was calculated after excluding SNPs related to QT interval and
CAD.
Results
The mean ages of the subjects in the Oregon-SUDS and the
WTCCC studies were 60.8612.6 and 51.467.5 years respectively
at time of event. Seventy two percent of SCD cases and 80.9% of
CAD controls were male. The genomic control factor (l) for this
analysis was 1.25. Based on the number of SNPs tested
(119,117 SNPs) a significance P-value cut off of 4.261027 was
determined. This level of correction for multiple testing is probably
conservative given that the MetaboChip array contains many
DNA variants in strong linkage disequilibrium, especially within
the fine-mapping sets. Nonetheless, we observed SNPs exceeding
the array-wide significance threshold (P=4.261027) as well as
genome-wide significance (P,561028) after correcting for lambda
inflation in two loci on chromosomes: 2q21 and 10q21 (Figure 1).
The association results of the lead variants at each of these loci are
shown in Table 1. The strongest associations were observed for the
intronic SNPs rs6730157 (P=4.93610212, OR=1.60, 95%)
within RAB3GAP1 and rs2077316 in the ZNF365 gene
(P=3.6461028, OR=2.41).
The association signal on 2q21 spans quite a large region with
multiple SNPs showing a significant association (Figure 1). In
conditional analysis, rs6730157 remained the most significant SNP
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and no other SNP in the region had a significant association
(P,0.01). Figure 2 shows the regional association plots for
rs6730157 and rs2077316.
Discussion
We have conducted a case-control association study using the
MetaboChip array to identify novel genetic variation associated
with SCD independent of CAD. The most significantly associated
SNP (rs6730157, P = 4.93610212) resides in an intronic region of
the RAB3GAP1 gene on chromosome 2q21. RAB3GAP1 encodes
the catalytic subunit of RabGTPase activating protein. RAB3GAP,
which is involved in regulation of RAB3 activity, is a heterodimeric
complex consisting of a 130-kD catalytic subunit. Mutations in
RAB3GAP1 are associated with Warburg micro syndrome, a rare
autosomal recessive syndrome characterized by microcephaly,
severe mental retardation and cataracts [29]. RAB3GAP1 is a key
regulator of calcium mediated hormone and neurotransmitter
exocytosis [30,31]. Interestingly, a previous study performed in a
yeast two-hybrid system and a rat dorsal root ganglion found that
a protein similar to human RAB3GAP1 interacts with intracellular
domains of SCN10A [32]. DNA variation within SCN10A has been
associated with abnormalities of cardiac ventricular depolariza-
tion, conduction, and ventricular fibrillation [33–36].
To test whether rs6730157 was located in a regulatory region or
transcription factor binding domain, we searched the ENCODE
project (Encyclopedia of DNA elements) database. We found that
rs6730157 is predicted to fall into a strong enhancer in several cell
types, including cardiac and aortic adventitial fibroblast cells [37].
However, it should be noted that although RAB3GAP1 is a strong
candidate gene in the chromosome 2 locus, the association signal
spans several others genes (Figure 2). At this stage, in common
with other GWAS findings, we cannot exclude the possibility that
the association is driven by another gene at this locus. Fine
mapping and functional analysis of the locus will be required to
refine the association.
The second significantly associated SNP (rs2077316,
P= 3.6461028) resides in an intronic region of the zinc finger
protein 365 gene (ZNF365) on chromosome 10q21. ZNF365
encodes several isoforms which have different expression patterns
and functions. ZNF365 has been implicated in breast cancer [38]
and Crohn’s disease [39] and a role in heart disease has not been
reported. According to ENCODE, no regulatory effects for
rs2077316 are currently predicted [37].
Our study has several limitations. Despite attempting to take
any population stratification into account using multi-dimensional
scaling, we observed an inflation of the genomic control factor
Figure 1. Manhattan plot of associated findings. Data is displayed as –log10P values against chromosomal location for the 119,117 SNPs that
were included in the statistical analysis. The dotted line represents the conservative significance threshold of P = 4.261027. The two loci that showed
an association at this level are plotted in red.
doi:10.1371/journal.pone.0059905.g001
Table 1. Summary of the two loci associated with SCD.
Chr SNP Gene Position Associatedallele
Associated allele
frequency SCD
cases
Associated allele
frequency CAD
controls SE OR
l Corrected P-
value
2 rs6730157 RAB3GAP1 135623558 G 0.37 0.26 0.06 1.60 4.93610212
10 rs2077316 ZNF365 63895454 C 0.060 0.026 0.14 2.41 3.6461028
Chr, chromosome; SE, standard error; OR, odds ratio.
doi:10.1371/journal.pone.0059905.t001
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statistic (l). This could be due to further differences in population
structure between the SCD cases and CAD controls which, while
all of European descent, are drawn from individuals from two
separate countries. Alternately, the design of the MetaboChip with
a possible over-representation of variants of relevance given the
choices of traits used to select the SNPs could contribute to an
inflation of this statistic. We tried to limit the impact of this by
excluding SNPs related to QT interval and CAD when calculating
the genomic control factor statistic. Most importantly, our findings
currently lack replication. In this context, although the association
at the 2q21 locus looks robust (with the association exceeding
GWA significance by several log values), particular caution needs
to be exercised in the interpretation of the finding at 10q21 as only
a single SNP with a very low minor allele frequency (Table 1)
showed an association. Replication of the findings is challenging
because of the rarity of collections of SCD subjects occurring in
the context of CAD. Nonetheless, in both cases our findings should
be considered provisional until further corroboration.
In summary, we provide evidence for two novel loci where
variants may affect risk of SCD in the context of CAD.
Understanding the mechanisms that increase risk of SCD is an
essential first step in trying to reduce this important complication
of CAD.
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